Phase I trial of cremophor EL with bolus doxorubicin

Clinical Cancer Research

Volumn 4, Issue 10, 1998, Pages 2321-2329

  Millward, Michael J ^a,b   Webster, Lorraine K ^a   Rischin, Danny ^a   Stokes, Kerrie H ^a   Toner, Guy C ^a   Bishop, James F ^a   Olver, Ian N ^a   Linahan, Bernadette M ^a   Linsenmeyer, Martha E ^a   Woodcock, David M ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CREMOPHOR; DOXORUBICIN; DOXORUBICINOL; GLYCOPROTEIN P; PACLITAXEL;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG METABOLISM; FEMALE; HEADACHE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; MALE; MELANOMA; MULTIDRUG RESISTANCE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CROSS-OVER STUDIES; DOXORUBICIN; FEMALE; GLYCEROL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; VEHICLES;

EID: 0031723119     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Bradley, G., Juranka, P. F., and Ling, V. Mechanism of multidrug resistance. Biochim. Biophys. Acta, 948: 87-128, 1988.
2. Gottesman, M. M. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res., 53: 747-754, 1993.
3. Seeber, S., Osieka, R., Schmidt, C. G., Achterrath, W., and Crooke, S. T. In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II). Cancer Res., 42: 4719-4725, 1982.
4. Roy, S. N., and Horwitz, S. B. A phosphoglycoprotein associated with Taxol resistance in J774.2 cells. Cancer Res., 45: 3856-3863, 1985.
5. Trock, B. J., Leonessa, F., and Clarke, R. Multidrug resistance in breast cancer: a meta-analysis of the occurrence and significance of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer Inst., 89: 917-931, 1997.
6. Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., Lieber, M., Cossman, J., Gottesman, M. M., and Pastan, I. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst., 81: 116-124, 1989.
7. Holzmayer, T. A., Hilsenbeck, S., Von Hoff, D. D., and Roninson, I. B. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J. Natl. Cancer Inst., 84: 1486-1491, 1992.
8. Chan, H. S. L., Thorner, P. S., Haddad, G., and Ling, V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol., 8: 689-704, 1990.
9. Dalton, W. S., Grogan, T. M., Meltzer, P. S., Scheper, R. J., Durie, B. G. M., Taylor, C. W., Miller, T. P., and Salmon, S. S. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol., 7: 415-424, 1989.
10. Millward, M. J., Cantwell, B. M. J., Munro, N. C., Robinson, A. M., Corns, P. A., and Harris, A. L. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br. J. Cancer, 67: 1031-1035, 1993.
11. Trump, D. L., Smith, D. C., Ellis, P. G., Rogers, M. P., Schold, S. C., Winer, E. P., Panella, T. J., Jordan, V. C., and Fine, R. L. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J. Natl. Cancer Inst., 84: 1811-1816, 1992.
12. Millward, M. J., Cantwell, B. M. J., Lien, E. A., Carmichael, J., and Harris, A. L. Intermittent high dose tamoxifen as a potential modifier of multidrug resistance. Eur. J. Cancer, 28: 805-810, 1992.
13. Bartlett, N. L., Lum, B. L., Fisher, G. A., Brophy, N. A., Ehsan, M. N., Halsey, J., and Sikic, B. I. Phase I trial of doxorubicin with cyclosporin as a modulator of multidrug resistance. J. Clin. Oncol., 12: 835-842, 1994.
14. Erlichman, C., Moore, M., Thiessen, J. J., Kerr, I. G., Walker, S., Goodman, P., Bjarnason, G., DeAngelis, C., and Bunting, P. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res., 53: 4837-4842, 1993.
15. Boote, D. J., Dennis, I. F., Twentyman, P. R., Osborne, R. J, Laburte, C., Hensel, S., Smyth, J. F., Brampton, M. H., and Bleehan, N. M. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol., 14: 610-618, 1996.
16. Hausdorff, I., Fisher, G. A., Halsy, J., Mallarino, M. C., Lum, B. L., and Sikic, B. I. Doxorubicin, paclitaxel, and oral PSC833, a modulator of multidrug resistance (MDR): a phase I trial. Proc. Am. Soc. Clin. Oncol., 15: 188, 1996.
17. Motzer, R. J., Lyn, P. L., Fischer, P., Ngo, R. L., Cordon-Cardo, C. and O'Brien, J. P. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J. Clin. Oncol., 13: 1958-1965, 1995.
18. Peck, R. A., Marshall, J. L., Ziessman, H. A., Hewett, J. L., Schmalbach, T., Chaturvedi, P., and Hawkins, M. J. Preliminary findings from a phase I/II trial of doxorubicin and VX-710. Ann. Oncol., 7 (Suppl. 1):, 101, 1996.
19. Cremophor EL. BASF Technical Leaflet MEF 074e, 1986.
20. Woodcock, D. M., Jefferson, S., Linsenmeyer, M. E., Crowther, P. J., Chojnowski, G. M., Williams, B., and Bertoncello, I. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res., 50: 4199-4203, 1990.
21. Woodcock, D. M., Linsenmeyer, M. E., Chojnowski, G., Kriegler, A. B., Nink, V., Webster, L. K., and Sawyer, W. H. Reversal of multidrug resistance by surfactants. Br. J. Cancer, 66: 62-68, 1992.
22. Friche, E., Jensen, P. B., Sehested, M., Demant, E. J., and Nissen, N. N. The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun., 2: 297-303, 1990.
23. Schuurhuis, G. J., Broxterman, H. J., Pinedo, H. M., van Heijningen, T. H., van Kalken, C. K., Vermorken, J. B., Spoelstra, E. C., and Lankelma, J. The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br. J. Cancer. 62: 591-594, 1990.
24. Hwang, M., Ahn, C-H., Pine, P. S., Yin, J. J., Hrycyna, C. A., Licht, T., and Aszalos, A. Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells. Int. J. Cancer, 65: 389-397, 1996.
25. Sinicrope, F. A., Dudeja, P. K., Bissonnette, B. M., Safa, A. R., and Brasitus, T. A. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J. Biol. Chem., 267: 24995-25002, 1992.
26. Dudeja, P. K., Anderson, K. M., Harris, J. S., Buckingham, L., and Coon, J. S. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch. Biochem. Biophys., 319: 309-315, 1995.
27. Webster, L., Linsenmeyer, M., Millward, M., Morton, C., Bishop, J., and Woodcock, D. Measurement of Cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistance phenotype. J. Natl. Cancer Inst., 85: 1685-1690, 1993.
28. Webster, L. K., Linsenmeyer, M. E., Rischin, D., Urch, M. E., Woodcock, D. M., and Millward, M. J. Plasma concentrations of polysorbate 80 in patients following docetaxel or etoposide. Cancer Chemother. Pharmacol., 39: 557-560, 1997.
29. Rischin, D., Webster, L. K., Millward, M. J., Linahan, B. M., Toner, G. C., Woollen, A. M., Morton, C. G., and Bishop, J. F. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J. Natl. Cancer Inst., 88: 1297-1301, 1996.
30. Lorenz, W., Reimann, H. J., Dormann, P., Schwarz, B., Neugebauer, E., and Doenicke, A. Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions, 7: 63-67, 1977.
31. Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., and Leyland-Jones, B. Hypersensitivity reactions from taxol. J. Clin. Oncol., 8: 1263-1268, 1990.
32. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
33. Maessen, P. A., Mross, K. B., Pinedo, H. M., and van der Vijgh, W. J. H. Improved method for the determination of 4′-epidoxorubicin and seven metabolites in plasma by high-pressure liquid chromatography. J. Chromatogr., 417: 339-346, 1987.
34. Soudon, J., Berlion, M., Lucas, C., Haddad, P., Bizzari, J-P., and Calvo, F. In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients. Cancer Chemother. Pharmacol., 36: 195-203, 1996.
35. Lehnert, M., de Guili, R., and Twentyman, P. R. Sensitive and rapid bioassay for analysis of P-glycoprotein-inhibiting activity of chemosensitizers in patient serum. Clin. Cancer Res., 2: 403-410, 1996.
36. Dunphy, F. R., Boyd, J. H., Kim, H. J., Dunphy, C. H., Harrison, B. R., Dunleavy, T. L., Rodriguez, J. J., McDonough, E. M., Minster, J. R., and Hilton, J. G. A Phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. Cancer (Phila.), 79: 2016-2023, 1997.
37. Itsubo, M., Ishikawa, T., Toda, G., and Tanaka, M. Immunohistochemical study of expression and cellular localisation of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer (Phila.), 73: 298-303, 1994.
38. Webster, L. K., Cosson, E. J., Stokes, K. H., and Millward, M. J. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br. J. Cancer, 73: 522-524, 1996.
39. Kerr, D. J., Graham, J., Cummings, J., Morrison, J. G., Thompson, G. G., Brodie, M. J., and Kaye, S. B. The effect of verapamil on the pharmacokinetics of Adriamycin. Cancer Chemother. Pharmacol., 18: 239-242, 1986.
40. Sonnevald, P., Marie, J-P., Huisman, C., Vekhoff, A., Schoester, M., Faussat, A. M., van Kapel, J., Groenewegen, A., Charnik, S., Zittoun, R., and Lowenberg, B. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A Phase I study. Leukemia (Baltimore). 10: 1741-1750, 1996.
41. Lum, B. L., Kaubisch, S., Yahanda, A. M., Adler, K. M., Jew, L., Ehsan, M. N., Brophy, N. A., Halsey, J., Gosland, M. P., and Sikic, B. L. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase 1 trial to modulate multidrug resistance. J. Clin. Oncol., 10: 1635-1642, 1992.
42. Berg, S. L., Tolcher, A. W., O'Shaughnessy, J. A., Denicoff, A. M., Noone, M., Ognibene, F. P., Cowan, K. H., and Balls, F. M. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J. Clin. Oncol., 13: 2039-2042, 1995.
43. Homes, F. A., Madden, T., Newman, R. A., Valero, V., Thierault, R. L., Fraschini, G., Walters, R. S., Booser, D. J., Buzdar, A. U., Willey, J., and Hortobagi, G. N. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a Phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol., 14: 2713-2721, 1996.
44. Gianni, L., Vigano, L., Locatelli, A., Capri, G., Giani, A., Tarenzi, E., and Bonadonna, G. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J. Clin. Oncol., 15: 1906-1915, 1997.
45. Berg, S. L., Cowan, K. H., Balis, F. M., Fisherman, J. S., Denicoff, A. M., Hillig, M., Poplack, D. G., and O'Shaughnessy, J. A. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J. Natl. Cancer Inst., 86: 143-145, 1994.
46. Tong, Y., Piraner, O. N., Doyle, L. A., Cornblatt, B., Chang, B., Yang, W., and Ross, D. D. Ethoxylated fatty acids (EOFAs), active components contained in cremophor EL, enhance daunorubicin (dnr) accumulation in P-glycoprotein (Pgp) but not multidrug resistance protein (MRP) overexpressing cells. Proc. Am. Assoc. Cancer Res., 36: 370, 1995.
47. Al-Khalili, A. H. E., Geetha, V., Balasubramanian, M., Allaudeen, H. S., Buckingham, L. E., Coon, J. S., and Emanuele, R. M. Fractionation of Cremophor EL to increase potency for reversing multidrug resistance. Proc. Am. Assoc. Cancer Res., 36: 371, 1995.
48. Buckinham, L. E., Balasubramanian, M., Safa, A. R., Shah, H., Komarov, P., Emanuele, R. M., and Coon, J. S. Reversal of multi-drug resistance in vitro by fatty acid-PEG-fatty acid diesters. Int. J. Cancer, 65: 74-79, 1996.
49. Bertoncello, I., Kriegler, A. B., Woodcock, D. M., Williams, B., Barber, L., and Nilsson, S. K. Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil. Int. J. Radiat. Biol., 67: 57-64, 1995.